9月29日晚，罗欣药业（维权）集团股份有限公司（下称"罗欣药业"）披露一则定增预案，计划向特定 对象发行不超过326276545股A股股票，募集资金总额不超过8.42亿元，拟用于创新药研发项目、原料药 改扩建及冻干车间技改项目，以及补充流动资金。本次发行不会导致其控制权发生变化。 拟使用募资2.53亿元"补流" 罗欣药业本次定增募资项目之一创新药研发项目投资总额2.26亿元，拟使用募集资金2.07亿元。创新药 研发项目包括注射用LX22001增加治疗消化性溃疡出血适应症的Ⅱ期及Ⅲ期临床研究项目、注射用 LX22001增加预防应激性溃疡出血适应症的Ⅲ期临床研究项目以及替戈拉生片增加预防阿司匹林相关消 化性溃疡适应症Ⅲ期临床研究项目。注射用LX22001的活性成分为替戈拉生，替戈拉生是一种钾离子竞 争性酸阻滞剂（P-CAB），为新型的抑制胃酸分泌的药物，也被称为酸泵拮抗剂（APA）。罗欣药业已 经成功研发国家1类创新药替戈拉生片。 罗欣药业表示，创新药研发项目为公司创新药注射用LX22001的研发，以及现有创新药替戈拉生片新增 适应症的研发，有利于拓展现有产品的治疗边界，在消化领域形成丰富的产品矩阵，增强客户黏性 ...

Group 1: Financial Performance - The company experienced a significant revenue decline in Q1 2025 due to reduced demand for respiratory and antibiotic products caused by a warm winter [2][3] - In Q4 2024, the company reported substantial losses primarily due to asset impairment provisions and fair value changes of financial instruments, which are non-operational impacts [3][5] - The company achieved profitability in Q1 2025, driven by increased sales of the innovative drug, Tegoprazan, and effective collection of receivables, improving cash flow and reducing bad debt losses [3][4] Group 2: Product Development and Pipeline - The innovative drug LX22001 is currently in Phase II clinical trials, while the clinical research report for Pucanatide tablets has been finalized and is moving towards commercialization [2][3] - The company has over 10 generic drugs in development or submitted for approval, which are expected to contribute to future revenue growth [3][4] Group 3: Market Strategy and Growth Plans - The company plans to significantly increase hospital access for its innovative drugs, with a target of a 130% increase in hospital entries by the end of 2024 [3][4] - The company is focusing on optimizing its supply chain and reducing fixed costs through various measures, including organizational restructuring and talent assessment [4][5] Group 4: Shareholder Information - As of May 9, 2025, the total number of shareholders is 31,442 [5]